HPV vaccine may work in fewer than three doses

The Cervarix vaccine for human papillomavirus (HPV) may provide protection with just one or two doses, rather than the standard three, according to an analysis of data from the National Cancer Institute (NCI)-sponsored Costa Rica Vaccine Trial.

Women participating in the study were to receive either three doses of Cervarix—intended to protect against HPV 16 and HPV 18—or the control vaccine. However, 20% of the 7,466 enrollees ultimately received fewer than three doses due to pregnancy, referrals to colposcopy, or other factors.

After excluding women who had no follow-up or who were HPV16 or HPV18 DNA-positive at enrollment, Aimée R. Kreimer, PhD, of the NCI's Division of Cancer Epidemiology and Genetics in Bethesda, Maryland, and colleagues found that 5,967 participants received three vaccine doses (2,957 HPV vaccine vs 3,010 control vaccine), 802 received two doses (422 HPV vs 380 control), and 384 received one dose (196 HPV vs 188 control).

Over 4 years of follow-up, similar levels of protection against HPV 16 and HPV 18 were seen among women in the three different HPV vaccine dose groups.

With three-dose regimens for HPV vaccines being expensive and difficult to complete, confirming the finding that fewer doses can be effective could help make primary prevention of cervical cancer a reality, wrote the investigators in Journal of the National Cancer Institute.

           

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs